Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Hepatology

• Publication date

  1999-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/00042737-199904000-00026PMID 10051494
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Analysis of Liver Disease, Nuclear HBcAg, Viral Replication, and Hepatitis B Virus DNA in Liver and Serum of HBcAg Vs. Anti‐HBe Positive Carriers of Hepatitis B Virus

  2007cited by this paper
• A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

  1998cited by this paper
• Lamivudine treatment for one year in previously untreated U.S. hepatitis B patients: histologic improvement and hepatitis be-antigen (HBeAg) seroconversion*

  1998cited by this paper
• Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective

  1998cited by this paper
• Lamivudine and intron a combination treatment in patients with chronic hepatitis B infection

  1998cited by this paper
• Identification and characterization of mutations in hepatitis B virus resistant to lamivudine

  1998cited by this paper
• Incidence, characteristics and clinical impact of lamivudine resistance in chronic hepatitis B

  1998cited by this paper
• Incidence and clinical significance of hepatitis B virus precore gene translation initiation mutations in e antigen‐negative patients

  1998cited by this paper
• Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group.

  1998cited by this paper
• Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: A placebo‐controlled trial

  1997cited by this paper
• Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study.

  1997cited by this paper
• A randomized, controlled trial of a 24‐month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum

  1997cited by this paper
• Therapy of hepatitis C: Overview

  1997cited by this paper
• Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation.

  1997cited by this paper
• Intra-observer variation in the histopathological assessment of chronic viral hepatitis

  1996cited by this paper
• Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine

  1996cited by this paper
• Hepatitis B virus carriers without precore mutations in hepatitis B e antigen‐negative stage show more severe liver damage

  1996cited by this paper
• Analysis of hepatitis B virus genotypes and pre‐core region variability during interferon treatment of HBe antigen negative chronic hepatitis B

  1996cited by this paper
• Intra-observer and inter-observer variation in the histopathological assessment of chronic viral hepatitis.

  1996cited by this paper
• Mutation in HBV RNA‐dependent DNA polymerase confers resistance to lamivudine in vivo

  1996cited by this paper
• Generation of duck hepatitis B virus polymerase mutants through site-directed mutagenesis which demonstrate resistance to lamivudine [(--)-beta-L-2', 3'-dideoxy-3'-thiacytidine] in vitro

  1996cited by this paper
• Treatment and prevention of chronic viral hepatitis.

  1995cited by this paper
• A preliminary trial of lamivudine for chronic hepatitis B infection.

  1995cited by this paper
• Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pre-genome encapsidation signal.

  1994cited by this paper
• Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B.

  1993cited by this paper
• Hepatitis B virus genotype A rarely circulates as an HBe-minus mutant: possible contribution of a single nucleotide in the precore region

  1993cited by this paper
• Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

  1993cited by this paper
• Phase II trial of lamivudine for chronic hepatitis B

  1993cited by this paper
• Anti-HBe-positive chronic hepatitis B with HBV-DNA in the serum response to a 6-month course of lymphoblastoid interferon.

  1992cited by this paper
• A randomized controlled trial of lymphoblastoid interferon‐α in patients with chronic hepatitis B lacking HBeAg

  1992cited by this paper
• Natural history and prognostic factors for chronic hepatitis type B.

  1991cited by this paper
• Interferon alfa-2b treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis type B.

  1990cited by this paper
• Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen

  1989cited by this paper
• Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection.

  1989cited by this paper
• The development of cirrhosis in patients with chronic type B hepatitis: A prospective study

  1988cited by this paper
• Contribution of low level HBV replication to continuing inflammatory activity in patients with anti-HBe positive chronic hepatitis B virus infection.

  1984cited by this paper
• Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

  1981cited by this paper
• Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis.

  1981cited by this paper
• Seroconversion from hepatitis B e antigen to anti-HBe in chronic hepatitis B virus infection

  1980cited by this paper
• Seroconversion from hepatitis B e antigen to anti-HBe in chronic hepatitis B virus infection.

  1980cited by this paper

• Chronic Hepatitis B Infection: Current and Emerging Therapeutic Strategies.

  2023cites this paper
• Effects of nucleos(t)ide analogs on hepatitis B surface antigen reduction with interferon‐lambda 3 induction in chronic hepatitis B patients

  2022cites this paper
• Screening for Hepatitis C Virus Infection in Adolescents and Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.

  2020cites this paper
• Peptides to combat viral infectious diseases

  2020cites this paper
• Screening for Hepatitis B Virus Infection in Nonpregnant Adolescents and Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.

  2020cites this paper
• Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis

  2020cites this paper
• A comparative network meta-analysis of standard of care treatments in treatment-naïve chronic hepatitis B patients.

  2020cites this paper
• Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a systematic review

  2020cites this paper
• Liver safety assessment in clinical trials of new agents for chronic hepatitis B

  2019cites this paper
• Risk factors for resistance development against lamivudine during long-term treatment of chronic hepatitis B virus infections

  2019cites this paper
• Antiviral treatment for treatment-naïve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials

  2019cites this paper
• Chronic Hepatitis B Infection: A Review

  2018cites this paper
• Hepatitis B virus e antigen-negative chronic infection. Treatment based on glutamic pyruvic transaminase and hepatitis B virus deoxyribonucleic acid cut-off values

  2018cites this paper
• Toward a Cure for Hepatitis B Virus Infection: Combination Therapy Involving Viral Suppression and Immune Modulation and Long-term Outcome

  2017cites this paper
• Factors Associated With Persistent Increase in Level of Alanine Aminotransferase in Patients With Chronic Hepatitis B Receiving Oral Antiviral Therapy

  2017cites this paper
• Hepatitis B virus e antigen-negative chronic infection. Treatment based on glutamic pyruvic transaminase and hepatitis B virus deoxyribonucleic acid cut-off values.

  2017cites this paper
• Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update)

  2017cites this paper
• Retrospective analysis of hepatitis B virus chronic infection in 247 patients: clinical stages, response to treatment and poor prognostic factors

  2017cites this paper
• On-treatment and off-treatment efficacy of entecavir in a real-life cohort of chronic hepatitis B patients

  2016cites this paper
• Antiviral therapy with nucleotide/nucleoside analogues in chronic hepatitis B: A meta-analysis of prospective randomized trials

  2016cites this paper
• Five-year results of oral antiviral therapy in HBeAg-negative chronic Hepatitis B.

  2016cites this paper
• Challenges in the management of chronic HBV infection in West Africa: The clinician’s perspective

  2016cites this paper
• Hepatitis B virus related cryoglobulinemic vasculitis: A multicentre open label study from the Gruppo Italiano di Studio delle Crioglobulinemie - GISC.

  2016cites this paper
• Nucleos(t)ide Analogue Based Therapy and Management of Patients

  2016cites this paper
• Flares during long‐term entecavir therapy in chronic hepatitis B

  2016cites this paper
• Baseline prognostic factors and statistic model to predict early virological response in lamivudine-treated patients with chronic hepatitis B.

  2015cites this paper
• Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation.

  2015cites this paper
• Chronic Hepatitis B Viral Infection

  2015cites this paper
• Change of strategies and future perspectives against hepatitis B virus recurrence after liver transplantation.

  2015cites this paper
• Natural YMDD-motif mutants affect clinical course of lamivudine in chronic hepatitis B.

  2015cites this paper
• Current and future antiviral drug therapies of hepatitis B chronic infection.

  2015cites this paper
• Screening for Hepatitis B Virus Infection in Nonpregnant Adolescents and Adults: Systematic Review to Update the 2004 U.S. Preventive Services Task Force Recommendation

  2014influential citation
• Hepatitis B Virus and Hepatitis Delta Virus

  2014cites this paper
• HBeAg negative variants and their role in the natural history of chronic hepatitis B virus infection.

  2014cites this paper
• Treatment cessation in noncirrhotic, e‐antigen negative chronic hepatitis B is safe and effective following prolonged anti‐viral suppression with nucleosides/nucleotides

  2014cites this paper
• Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease

  2014cites this paper
• The importance of baseline viral load when assessing relative efficacy in treatment-naïve HBeAg-positive chronic hepatitis B: a systematic review and network meta-analysis

  2014cites this paper
• JSH Guidelines for the Management of Hepatitis B Virus Infection

  2014cites this paper
• Chronic hepatitis B in 2014: great therapeutic progress, large diagnostic deficit.

  2014cites this paper
• Practical approach in hepatitis B e antigen-negative individuals to identify treatment candidates.

  2014cites this paper
• Abbott RealTime HBV Assay Is More Sensitive in Detection of Low Viral Load and Little Impacted by Drug Resistant Mutation in Chronic Hepatitis B Patients under Nucleot(s)ide Analogues Therapy

  2014cites this paper
• Screening for Hepatitis B Virus Infection in Adolescents and Adults: A Systematic Review to Update the U.S. Preventive Services Task Force Recommendation

  2014influential citation
• Can Nucleos(t)ide Analogue (NA) Therapy Ever be Stopped in HBeAg-Negative Chronic Hepatitis B?

  2014cites this paper
• Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues

  2013cites this paper
• Why do I treat HBeAg‐negative chronic hepatitis B patients with nucleos(t)ide analogues?

  2013cites this paper
• [Characteristics of patients with chronic hepatitis B virus infection. analysis of a series of 474 patients].

  2013cites this paper
• Frequency of precore/core mutants in chronic Hepatitis B cases.

  2013cites this paper
• B型肝炎治療ガイドライン（第1.1版）

  2013cites this paper
• Traitement de l’hépatite chronique B

  2013cites this paper
• An optimized antiviral modification strategy for prevention of hepatitis B reactivation in patients undergoing prophylactic lamivudine and chemotherapy: a pilot study

  2013cites this paper
• Prevalence and Factors Associated with Hepatitis B Virus Infection Among Senior Citizens in a Southern Brazilian City

  2013cites this paper
• Kronik Hepatit B Tedavisinde Pegile İnterferon Alfa ile Lamivudin Monoterapilerinin Karşılaştırılması

  2013cites this paper
• Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir.

  2012cites this paper
• HEPATİT B VİRÜS ENFEKSİYONUNDA GÜNCEL TEDAVİ YAKLAŞIMLARI

  2012cites this paper
• EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.

  2012cites this paper
• What MELD score mandates use of entecavir for ACLF-HBV HBeAg-negative patients?

  2012cites this paper
• Hepatitis B and Hepatocellular Carcinoma and Their Treatment

  2012cites this paper
• Characterization of Hepatitis B Viral Drug Resistance inIndian Subcontinent Patients with Chronic Liver Disease.

  2012cites this paper
• YMDD motif mutations in chronic hepatitis B antiviral treatment naïve patients: a multi-center study.

  2012cites this paper
• Hepatitis B-associated fibrosis and fibrosis/cirrhosis regression with nucleoside and nucleotide analogs

  2012cites this paper
• Direct Acting Antivirals for the Treatment of Chronic Viral Hepatitis

  2012cites this paper
• Natural Course, Therapeutic Options and Economic Evaluation of Therapies for Chronic Hepatitis B

  2012cites this paper
• Maternal-Fetal Transmission of HBV

  2012cites this paper
• Treatment of HBeAg‐negative chronic hepatitis B patients with nucleos(t)ide analogues

  2011cites this paper
• Hepatitis B therapy

  2011cites this paper
• Hepatitis B and D

  2011cites this paper
• Systematic Review of the Literature on Comparative Effectiveness of Antiviral Treatments for Chronic Hepatitis B Infection

  2011cites this paper
• FREQUENCY OF YMDD MUTATIONS IN PATIENTS WITH CHRONIC HEPATITIS B UNTREATED WITH ANTIVIRAL MEDICINES

  2011cites this paper
• Identification of Drug Resistant Mutants of HBV (Hepatitis B Virus) by Direct Sequencing in Iranian Patients Treated with Lamivudine

  2011cites this paper
• Milestones and perspectives in viral hepatitis B

  2011cites this paper
• High Rate of Complete Viral Suppression With Combination Therapy in Patients With Chronic Hepatitis B and Prior Treatment Failure

  2011cites this paper
• Antiviral drugs for HBV liver disease

  2011cites this paper
• Viral Infections by Nonhepatotropic Viruses

  2010cites this paper
• Antiviral Therapy: Analysis of Long-term Efficacy and Safety

  2010cites this paper
• Adefovir plus lamivudine are more effective than adefovir alone in lamivudine‐resistant HBeAg‐ chronic hepatitis B patients: A 4‐year study

  2010cites this paper
• 13 Résultats des essais thérapeutiques dans l’hépatite chronique B

  2010cites this paper
• Kosteneffectiviteit van antivirale behandeling voor chronische hepatitis B in België

  2010cites this paper
• Hepatitis B: Prognosis and Treatment

  2010cites this paper
• Chronic Viral Hepatitis

  2010cites this paper
• A Review of Oral Antiretroviral Therapy for the Treatment of Chronic Hepatitis B

  2010cites this paper
• Cost-effectiveness of antiviral treatment of chronic hepatitis B in Belgium

  2010cites this paper
• DNA-guided hepatitis B treatment, viral load is essential, but not sufficient

  2009cites this paper
• Current treatment of chronic HBV infection: A European perspective

  2009cites this paper
• Efficacy of Pre-S-containing HBV Vaccine Combined with Lamivudine in the Treatment of Chronic HBV Infection

  2009cites this paper
• Antiviral combination therapy for treatment of chronic hepatitis B, hepatitis C, and human immunodeficiency virus infection.

  2009cites this paper
• Current treatment of chronic HBV infection: An Asian-Pacific perspective

  2009cites this paper
• Recommandations de pratiques cliniques de l’EASL. Prise en charge de l’hépatite chronique B EASL Clinical Practice Guidelines. Management of chronic hepatitis B European Association for the Study of the Liver

  2009cites this paper
• Rapid HBV DNA decrease (week 12) is an important prognostic factor for first-line treatment with adefovir dipivoxil for chronic hepatitis B

  2009cites this paper
• Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy.

  2009cites this paper
• Pharmacotherapy of Chronic Hepatitis B in Adults: Focus on Tenofovir Disoproxil Fumarate

  2009cites this paper
• Benefits and risks of nucleoside analog therapy for hepatitis B

  2009cites this paper
• RECOMMANDATIONS Recommandations de pratiques cliniques de l ’ EASL . Prise en charge de l ’ hépatite chronique B EASL Clinical Practice Guidelines . Management of chronic hepatitis B European Association for the Study of the Liver

  2009cites this paper
• EASL Clinical Practice Guidelines: management of chronic hepatitis B.

  2009cites this paper
• Chronic hepatitis B: Update 2009

  2009cites this paper
• Clinical Experience with Long-term Lamivudine Therapy to Determine the Adequate Duration of Treatment in Children and Adolescents with HBeAg-Negative Chronic Hepatitis B

  2009cites this paper
• Analogs and fibrosis regression in hepatitis B Analogues et régression de la fibrose dans l’hépatite B

  2009cites this paper
• HBE antijen negatif kronik Hepatit B'li hastalarda Lamivudin tedavisinin etkinliği

  2009influential citation
• DNA-guided hepatitis B treatment, viral load is essential, but not sufficient.

  2009cites this paper
• [EASL clinical practice guidelines. Management of chronic hepatitis B].

  2009cites this paper
• Analogs and fibrosis regression in hepatitis B.

  2009cites this paper